Trinity Capital, an international alternative asset manager, committed $50 million in growth capital to Cala Health, a bioelectronic medicine company developing wearable neuromodulation therapies for tremors.
“Cala Health has developed a therapy that we believe is simple, personalized and effective for patients,” Rob Lake, senior managing director of life sciences at Trinity Capital, said. “We are proud to partner with a company that is delivering meaningful improvements in patients’ daily lives and look forward to supporting their continued growth and commercial expansion.”
Deanna Harshbarger, CEO of Cala, said, “We are pleased to partner with the Trinity team to optimize our capital structure. This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS therapy to impact the lives of essential tremor and Parkinson’s disease patients.”
